These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 2804373)

  • 21. Type 2M:Milwaukee-1 von Willebrand disease: an in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets.
    Mancuso DJ; Kroner PA; Christopherson PA; Vokac EA; Gill JC; Montgomery RR
    Blood; 1996 Oct; 88(7):2559-68. PubMed ID: 8839848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factor VIII:C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease.
    Castaman G; Lattuada A; Mannucci PM; Rodeghiero F
    Br J Haematol; 1995 Jan; 89(1):147-51. PubMed ID: 7833254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Reliable von Willebrand factor: ristocetin cofactor enzyme-linked immunosorbent assay to differentiate between type 1 and type 2 von Willebrand disease.
    Vanhoorelbeke K; Cauwenberghs N; Vandecasteele G; Vauterin S; Deckmyn H
    Semin Thromb Hemost; 2002 Apr; 28(2):161-6. PubMed ID: 11992239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Absence of a bleeding tendency in severe acquired von Willebrand's disease. The role of platelet von Willebrand factor in maintaining normal hemostasis.
    Drouin J; Lillicrap DP; Izaguirre CA; Sutherland M; Windsor S; Benford K; Hoogendorn H; Giles AR
    Am J Clin Pathol; 1989 Oct; 92(4):471-8. PubMed ID: 2508465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Type 2M vWD resulting from a lysine deletion within a four lysine residue repeat in the A1 loop of von Willebrand factor.
    Hilbert L; Jenkins PV; Gaucher C; Meriane E; Collins PW; Pasi KJ; Mazurier C
    Thromb Haemost; 2000 Aug; 84(2):188-94. PubMed ID: 10959688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Function of von Willebrand factor after crossed bone marrow transplantation between normal and von Willebrand disease pigs: effect on arterial thrombosis in chimeras.
    Nichols TC; Samama CM; Bellinger DA; Roussi J; Reddick RL; Bonneau M; Read MS; Bailliart O; Koch GG; Vaiman M
    Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2455-9. PubMed ID: 7708664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
    Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New variant of type II von Willebrand's disease with structural abnormality of plasma von Willebrand factor in a patient with very mild bleeding history.
    Baillod P; Gaucher C; Affolter B; Mazurier C; Pflugshaupt R
    Am J Hematol; 1995 May; 49(1):21-8. PubMed ID: 7741134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigation of a case of subtype IIC von Willebrand disease: characterization of the variability of this subtype.
    Mazurier C; Mannucci PM; Parquet-Gernez A; Goudemand M; Meyer D
    Am J Hematol; 1986 Jul; 22(3):301-11. PubMed ID: 3087159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of von Willebrand factor in platelets of patients with various forms of von Willebrand disease: is there a clinical relevance?
    Kertzscher F; Müller AE; Lenk H
    Eur J Pediatr; 1999 Dec; 158 Suppl 3():S177-9. PubMed ID: 10650864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.
    Giannini S; Mezzasoma AM; Leone M; Gresele P
    Haematologica; 2007 Dec; 92(12):1647-54. PubMed ID: 18055988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Oct; 12(4):397-420. PubMed ID: 17000885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Agglutination of formalin-fixed, platelet-type von Willebrand's disease platelets by human von Willebrand factor.
    Takahashi H; Shibata A
    Thromb Haemost; 1984 Dec; 52(3):267-70. PubMed ID: 6241752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
    Michiels JJ; van Vliet HH
    Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Studies of the pathophysiology of acquired von Willebrand's disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies.
    Mannucci PM; Lombardi R; Bader R; Horellou MH; Finazzi G; Besana C; Conard J; Samama M
    Blood; 1984 Sep; 64(3):614-21. PubMed ID: 6432075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease.
    Ruggeri ZM; Pareti FI; Mannucci PM; Ciavarella N; Zimmerman TS
    N Engl J Med; 1980 May; 302(19):1047-51. PubMed ID: 6767976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heterogeneity in type IIB von Willebrand disease: two unrelated cases with no family history and mild abnormalities of ristocetin-induced interaction between von Willebrand factor and platelets.
    Federici AB; Mannucci PM; Bader R; Lombardi R; Lattuada A
    Am J Hematol; 1986 Dec; 23(4):381-90. PubMed ID: 3491540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.